We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Microsurgery Preferred for Resecting Rectal Lesions

By HospiMedica staff writers
Posted on 11 Jul 2007
A new study suggests that transanal endoscopic microsurgery (TEM) may offer certain advantages over transanal excision (TA), the most common method of surgically excising local rectal lesions. More...


Researchers at the University of Vermont (Burlington, USA) conducted a study that compared TEM with TA for both benign and malignant rectal masses. The cohort encompassed 171 patients who underwent either TA or TEM (82 patients TEM, 89 TA) for adenocarcinoma or polyps between 1990 and 2006. Both patient groups were similar in demographics such as age, sex, and lesion type, stage, and size, with a mean follow-up of 34 months.

Results showed the TEM procedure was much more likely to result in a complete resection and yield negative margins, as compared with TA (88% vs. 71%). This was true whether the lesion was benign or malignant. It was also more likely to produce an intact, non-fragmented specimen, as compared with TA (94% vs. 63%). The rate of recurrence, both local and distant, was also lower in patients who had undergone TEM, as compared with TA (5% vs. 25%). This was particularly true for rates of local recurrence, which were significantly lower for both benign and malignant lesions following TEM (4% vs. 20%). The rate of complications was similar between both groups. The study was presented at the 2007 annual meeting of the American Society Colon and Rectal Surgeons, held during June 2007 in St. Louis (MO, USA).

"Overall, rectal access is vastly superior with transanal endoscopic microsurgery, because you can visualize the entire rectum,” said lead author Peter Cataldo, M.D., an associate professor of surgery at Vermont. "The visualization is superior to transanal excision, and these attributes translate into a much more precise incision enclosure of the rectal masses.”


Related Links:
University of Vermont

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Radiation Safety Barrier
RayShield Intensi-Barrier
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.